Cardiovascular adverse effects of lopinavir/ritonavir and hydroxychloroquine in COVID-19 patients: Cases from a single pharmacovigilance centre

In this article we summarize the cardiovascular adverse events that were observed in three patients during their treatment for COVID-19 and discuss their association with lopinavir/ ritonavir (LPV/r) and hydroxychloroquine (HCQ). The cases were reported to our regional pharmacovigilance centre in Ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Istampoulouoglou, Ioanna, Zimmermanns, Barbara, Grandinetti, Tanja, Marzolini, Catia, Harings-Kaim, Annette, Koechlin-Lemke, Sarah, Scholz, Irene, Bassetti, Stefano, Leuppi-Taegtmeyer, Anne B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Magdi Yacoub Heart Foundation 2021
Materias:
Pharmacovigilance
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272412/
https://www.ncbi.nlm.nih.gov/pubmed/34285902
http://dx.doi.org/10.21542/gcsp.2021.11

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272412/
https://www.ncbi.nlm.nih.gov/pubmed/34285902
http://dx.doi.org/10.21542/gcsp.2021.11

Ejemplares similares